Despite the retrospective design, our findings show that EGFR-TKI rechallenge should be considered as a standard treatment after failure of EGFR-TKI in elderly patients with advanced NSCLC with T790M-negative EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.